These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 15135788)

  • 1. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The place of pegvisomant in the management of acromegaly.
    Parkinson C; Trainer PJ
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acromegaly: new principles for treatment].
    Jørgensen JO; Feldt-Rasmussen UF; Andersen M; Kristensen LØ; Laurberg P; Weeke J
    Ugeskr Laeger; 2007 Mar; 169(10):904-6. PubMed ID: 17359733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
    Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
    Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly.
    Holdaway IM
    Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
    Paisley AN; Trainer P; Drake W
    Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
    Frohman LA; Bonert V
    Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy for acromegaly].
    Góth M
    Orv Hetil; 2013 Sep; 154(39):1527-34. PubMed ID: 24058097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological therapy for acromegaly: a critical review.
    Muller AF; Van Der Lely AJ
    Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.